Pediatric acute lymphoblastic leukemia relapse and prognosis: key predictors and therapeutic implications

Thrombocytopenia at diagnosis, <i>BCR::ABL1</i>(+), and persistent MRD are critical relapse predictors. HSCT remains pivotal for bone marrow relapse. Incorporating platelet counts into risk stratification and optimizing MRD-guided bridging therapies may enhance outcome. Future research should prioritize thrombocytopenia mechanisms and HSCT preconditioning strategies.